Harvard Bioscience Statistics
Total Valuation
HBIO has a market cap or net worth of $20.50 million. The enterprise value is $59.56 million.
Important Dates
The next estimated earnings date is Thursday, August 7, 2025, before market open.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
HBIO has 44.21 million shares outstanding. The number of shares has increased by 2.27% in one year.
| Current Share Class | 44.21M |
| Shares Outstanding | 44.21M |
| Shares Change (YoY) | +2.27% |
| Shares Change (QoQ) | -0.81% |
| Owned by Insiders (%) | 7.60% |
| Owned by Institutions (%) | 51.85% |
| Float | 33.97M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 13.94 |
| PS Ratio | 0.23 |
| Forward PS | 0.23 |
| PB Ratio | 1.45 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 40.11 |
| P/OCF Ratio | 6.78 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 20.05, with an EV/FCF ratio of 116.55.
| EV / Earnings | n/a |
| EV / Sales | 0.65 |
| EV / EBITDA | 20.05 |
| EV / EBIT | n/a |
| EV / FCF | 116.55 |
Financial Position
The company has a current ratio of 0.81, with a Debt / Equity ratio of 3.01.
| Current Ratio | 0.81 |
| Quick Ratio | 0.34 |
| Debt / Equity | 3.01 |
| Debt / EBITDA | 8.63 |
| Debt / FCF | 87.29 |
| Interest Coverage | -1.25 |
Financial Efficiency
Return on equity (ROE) is -138.80% and return on invested capital (ROIC) is -2.99%.
| Return on Equity (ROE) | -138.80% |
| Return on Assets (ROA) | -2.38% |
| Return on Invested Capital (ROIC) | -2.99% |
| Return on Capital Employed (ROCE) | -16.78% |
| Revenue Per Employee | $257,456 |
| Profits Per Employee | -$163,524 |
| Employee Count | 355 |
| Asset Turnover | 0.86 |
| Inventory Turnover | 1.67 |
Taxes
In the past 12 months, HBIO has paid $76,000 in taxes.
| Income Tax | 76,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -83.96% in the last 52 weeks. The beta is 1.55, so HBIO's price volatility has been higher than the market average.
| Beta (5Y) | 1.55 |
| 52-Week Price Change | -83.96% |
| 50-Day Moving Average | 0.41 |
| 200-Day Moving Average | 1.45 |
| Relative Strength Index (RSI) | 48.87 |
| Average Volume (20 Days) | 4,128,044 |
Short Selling Information
The latest short interest is 2.83 million, so 6.41% of the outstanding shares have been sold short.
| Short Interest | 2.83M |
| Short Previous Month | 6.64M |
| Short % of Shares Out | 6.41% |
| Short % of Float | 8.34% |
| Short Ratio (days to cover) | 0.09 |
Income Statement
In the last 12 months, HBIO had revenue of $91.40 million and -$58.05 million in losses. Loss per share was -$1.33.
| Revenue | 91.40M |
| Gross Profit | 52.22M |
| Operating Income | -4.06M |
| Pretax Income | -9.43M |
| Net Income | -58.05M |
| EBITDA | 2.97M |
| EBIT | -4.06M |
| Loss Per Share | -$1.33 |
Full Income StatementBalance Sheet
The company has $5.55 million in cash and $44.61 million in debt, giving a net cash position of -$39.06 million or -$0.88 per share.
| Cash & Cash Equivalents | 5.55M |
| Total Debt | 44.61M |
| Net Cash | -39.06M |
| Net Cash Per Share | -$0.88 |
| Equity (Book Value) | 14.84M |
| Book Value Per Share | 0.34 |
| Working Capital | -10.70M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $3.02 million and capital expenditures -$2.51 million, giving a free cash flow of $511,000.
| Operating Cash Flow | 3.02M |
| Capital Expenditures | -2.51M |
| Free Cash Flow | 511,000 |
| FCF Per Share | $0.01 |
Full Cash Flow StatementMargins
Gross margin is 57.14%, with operating and profit margins of -4.44% and -63.52%.
| Gross Margin | 57.14% |
| Operating Margin | -4.44% |
| Pretax Margin | -63.43% |
| Profit Margin | -63.52% |
| EBITDA Margin | 3.25% |
| EBIT Margin | -4.44% |
| FCF Margin | 0.56% |
Dividends & Yields
HBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.27% |
| Shareholder Yield | -2.27% |
| Earnings Yield | -283.21% |
| FCF Yield | 2.49% |
Analyst Forecast
The average price target for HBIO is $3.00, which is 547.11% higher than the current price. The consensus rating is "Buy".
| Price Target | $3.00 |
| Price Target Difference | 547.11% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
HBIO has an Altman Z-Score of -1.82 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.82 |
| Piotroski F-Score | 3 |